Nexgel, Inc. Stock: price and insider trades · United States

From a reporting standpoint, the company describes four distinct lines of business: contract manufacturing, custom & white label, consumer branded products, and medical devices/other. That mix is important because it shows NEXGEL is not just a branded-products story; it also monetizes manufacturing know-how and formulation capabilities through third-party and private-label work. Key branded offerings mentioned in company materials include Fever Cool, Hexagel, ClearComfort, and Nip Defense, along with newer initiatives such as TURFGUARD. The company positions itself as a provider of flexible hydrogel solutions for OTC medications, wound care, and cosmetics, with an emphasis on comfort and low skin irritation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/form10-k.htm?utm_source=openai))

Competitively, NEXGEL occupies a niche within the broader health, beauty, and medtech ecosystem. Its edge lies in the formulation of high-water-content patches and gels that can be tailored for sensitive-skin use and differentiated delivery characteristics. At the same time, it faces competition from larger medical-device, consumer-health, and personal-care companies with broader distribution and greater scale. Management has attempted to strengthen the operating model by partnering on manufacturing and packaging capacity; notably, the 2023 joint venture with C.G. Laboratories was intended to improve capacity, margins, and supply-chain efficiency. ([ir.nexgel.com](https://ir.nexgel.com/news-events/press-releases/detail/47/nexgel-acquires-50-interest-in-newly-formed-joint-venture?utm_source=openai))

Geographically, the company remains primarily U.S.-based, with operations centered in Pennsylvania and commercial efforts expanded through independent sales representation. Recent corporate developments include a February 2026 financing tied to a potential acquisition, the filing of the 2025 annual report, and multiple Form 4 insider transaction filings in 2025, which underline the active monitoring of insider ownership changes on this NASDAQ name. For international equity investors, NEXGEL offers a healthcare-oriented niche growth narrative with potential upside from product expansion and manufacturing scale, but it should be viewed as a speculative small-cap with meaningful balance-sheet and execution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1468929/000149315226006124/ex99-1.htm?utm_source=openai))